Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

GERMAN drug developer BioNTech has signed an agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) to manufacture ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the ...

DelveInsight's,“ Advanced Melanoma Pipeline Insight 2025 ” report provides comprehensive insights about 55+ companies and 60+ pipel ...

US factory activity contracted in May for a third consecutive month and a gauge of imports fell to a 16-year low as firms ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s BNT-327 in a deal possibly worth over $11 ...

US stocks closed higher on Monday (June 2), the first trading session of June, as markets shrugged off mounting global trade ...

Bristol-Myers announces $11 billion cancer partnership with BioNTech. CEO Boerner dubs the team up the next new frontier in ...